1 / 10

Reasons for Non-participation and Treatment Outcomes in Atrial Fibrillation Study

This study by Jonathan Mant et al. published in The Lancet investigates the reasons patients with atrial fibrillation did not participate in clinical trials. It analyzes baseline characteristics of patients treated with warfarin versus aspirin, adherence rates, and the nature of primary events. The study includes Kaplan-Meier plots illustrating time to primary events and relative risks of primary outcomes by patient subgroup. Notably, it provides an indirect comparison of ischaemic stroke and major hemorrhage risks between anticoagulation and aspirin across various trials.

tadeo
Télécharger la présentation

Reasons for Non-participation and Treatment Outcomes in Atrial Fibrillation Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trial profile Jonathan Mant, et al. Lancet 2007;370:493-503

  2. Reasons why patients identified with atrial fibrillation did not take part in the study Jonathan Mant, et al. Lancet 2007;370:493-503

  3. Baseline characteristics of patients subsequently treated with warfarin or aspirin Jonathan Mant, et al. Lancet 2007;370:493-503

  4. Kaplan-Meier plot of adherence to allocated treatment Jonathan Mant, et al. Lancet 2007;370:493-503

  5. Nature of primary events Jonathan Mant, et al. Lancet 2007;370:493-503

  6. Kaplan-Meier plot of time to primary event Jonathan Mant, et al. Lancet 2007;370:493-503

  7. Relative risk of all primary events by subgroup Jonathan Mant, et al. Lancet 2007;370:493-503

  8. Risk of primary event and major haemorrhage by treatment allocation for different patient subgroups Jonathan Mant, et al. Lancet 2007;370:493-503

  9. Risk of secondary and composite outcomes by treatment allocation for different patient subgroups Jonathan Mant, et al. Lancet 2007;370:493-503

  10. Indirect comparison of results from BAFTA for ischaemic stroke and major haemorrhage with results from six other randomised trials of aspirin versus anticoagulation Jonathan Mant, et al. Lancet 2007;370:493-503

More Related